In 2017, 3 years after anti PD-1/PD-L1 therapy started to be used, the Food and Drug Administration (FDA) approved the use of nivolumab—including in patients with fully resectioned melanoma—but that, however, had distant metastases or lymphonodular metastases, thus targeting patients in stages IIIB, IIIC, and IV. This evidence concerns the gene CD274 and melanoma.